Behind the ordering catalog sit more than 23,000 individual services and products, assembled across four decades of work with discovery groups. Study lines are grouped by small molecule, biotherapeutic, integrated drug discovery, therapeutic area and research phase, with custom routes for requests that fit none of those. Reagent and kit families cover assay ready kits, cell lines and primary cells, detection kits and reagents, recombinant proteins and kinases, bioassays for biologics, and membrane preparations, sold under the DiscoverX brand out of laboratories in the San Francisco Bay Area. A process chemistry team adds process development, route optimization and kilogram-scale synthesis, closing the gap between discovery chemistry and clinical supply. Recent method work includes SH2scan for scalable SH2 domain profiling to surface off-target liabilities during SAR decisions, modernized in vitro safety pharmacology packages, and tuning of receptor density in GPCR cell systems to set assay sensitivity. A scientific advisory board guides technical direction.
Eurofins Discovery
Eurofins Discovery is a market-leading CRO that supports global drug discovery researchers with an unparalleled suite of products and services, including in vitro screening, cell-based assays, pharmacology, and ADME-Tox profiling. By delivering high-quality, reproducible data and deep scientific expertise, the company accelerates the transition of small molecules and biologics from early-stage discovery into preclinical development.
The Latest Insights & Innovations from
Eurofins Discovery
No items found.
Blog
What Is the NAMs Initiative and How Does the U.S. Government-backed Health Program Constitute an Animal Alternative?
March 7, 2024
Learn more
No items found.
No items found.